|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Goodwill impairment | |||||
| Intangibles and long-lived asset impairment | |||||
| Long-lived asset and intangibles impairment | |||||
| Productivity and transformation costs | |||||
| Amortization of acquired intangible assets | |||||
| Proceeds from insurance claim | |||||
| Operating loss | |||||
| Interest and other financing expense, net | |||||
| Other expense, net | |||||
| Total | |||||
| (Benefit) provision for income taxes | |||||
| Equity in net loss of equity-method investees | |||||
| Net loss | |||||
| Net loss per common share: | |||||
| Basic | |||||
| Diluted | |||||
| Shares used in the calculation of net loss per common share: | |||||
| Basic | |||||
| Diluted | |||||
Loading...